Maastricht University

The Department of Precision Medicine is an disease and discipline-agnostic department with international group of highly motivated researchers at the University of Maastricht. The Department of Precision Medicine consists out of The D-Lab, an AI lab focused on Decision Support System (DSS), the M-Lab, a molecular lab focusing on targeting the tumour microenvironment and using genetically modified bacteria colonizing the microbiome for therapeutic purposes and the the Clinical Trial Unit+ (CTU), the CTU is a datacenter specialized in (virtual) clinical trials and In Silico experiments based on real and synthetic data.

Role of institution in the project

The D-Lab involved in EUCAIM, excels at applying machine learning methods, such as deep learning, on vast amounts of medical data in order to improve the lives of patients, with a focus on decision support systems and personalizing treatment. Its scientists are one of the inventors of “Distributed learning” a revolutionary Big Data approach for health care, “Radiomics” and “multifactorial Decision Support Systems” and have extensive experience in transformation of patient data into clinical tools, translational medicine and subsequent entrepreneurial activities, semantic web technology, ethics involved with personal medical data ownership and utilization and in silico simulation of cancer.

Prof. Dr. Philippe Lambin

Prof. Dr. Philippe Lambin (“ERC Advanced” Grant laureate) is a clinician, radiation oncologist and a pioneer in translational research with a focus on imaging (he published the first paper on Radiomics and was senior author of the most cited Radiomics paper) and Big Data in health care. He has successfully led multiple multicentric trials (e.g. and has been praised for his leadership. He has a PhD in Radiation Biology and is head of the department of the Precision medicine at the Maastricht University. He was one of the international experts in the Flims workshop “Methods in Clinical Cancer Research organized jointly by the FECS, AACR and ASCO and he is leading several clinical trials (see his name is mentioned as Principal Investigator in 30 clinical trials). He was principle investigator of more than 38 research grants (totaling over €50 million) and is currently involved in several successful European grants. His main areas of interest are directed towards multifactorial Decision Support. It is from this background that he has a keen interest in the development of Big Data –based health care solutions and treatment targeting the tumour microenvironment.

Join the EUCAIM Consortium

Open Call for New Beneficiaries

We’re inviting new partners to enhance our pan-European infrastructure for cancer images and artificial intelligence.

Whether you’re a data holder with valuable cancer images or an innovator developing AI tools for precision medicine, this is your chance to contribute to a groundbreaking project.

Apply by 10 June 2024!

Open Call Webinar

We recently hosted a webinar with more details for prospective applicants to the open call. A recording is available.

Our open Call for new collaborators
launches in April 2024

Opportunities for data holders & AI developers to contribute await! Let‘s join forces to enhance cancer diagnosis and treatment

Be the first to know and apply!

March 14, 10:00-11:30 aM CET



Explore the potential for AI-driven cancer care advancements!
Learn how to access and utilize our federated cancer image repository. The webinar is for AI Innovators & Data Providers interested in the platform and will feature an introduction to EUCAIM & Cancer Image Europe and a demonstration of data exploration & access.

Survey Invitation

Join Leading Experts In Shaping AI In Cancer

EUCAIM is looking for your feedback! We have recently published a Stakeholder Survey in order to reach out to potential end-users and stakeholders. We believe that your insights could significantly contribute to understanding the expectations of potential users and identifying the essential aspects that stakeholders find crucial for future engagement and collaboration with the platform.

Therefore, we would like to invite you to participate in the Stakeholder Survey about the Cancer Image Europe platform.

Completing the survey will take approximately 10 minutes. Your participation is crucial to the success of this project, and we deeply appreciate your expertise in shaping the future of cancer imaging and treatment.